Emergent Biosolutions Net Income 2010-2022 | EBS

Emergent Biosolutions net income from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Emergent Biosolutions Annual Net Income
(Millions of US $)
2021 $231
2020 $305
2019 $55
2018 $63
2017 $83
2016 $52
2015 $63
2014 $37
2013 $31
2012 $24
2011 $23
2010 $52
2009 $31
Emergent Biosolutions Quarterly Net Income
(Millions of US $)
2022-09-30 $-76
2022-06-30 $-56
2022-03-31 $-4
2021-12-31 $189
2021-09-30 $-33
2021-06-30 $5
2021-03-31 $70
2020-12-31 $185
2020-09-30 $40
2020-06-30 $93
2020-03-31 $-13
2019-12-31 $47
2019-09-30 $43
2019-06-30 $-10
2019-03-31 $-26
2018-12-31 $-3
2018-09-30 $21
2018-06-30 $50
2018-03-31 $-5
2017-12-31 $34
2017-09-30 $34
2017-06-30 $5
2017-03-31 $10
2016-12-31 $37
2016-09-30 $21
2016-06-30 $-11
2016-03-31 $4
2015-12-31 $33
2015-09-30 $37
2015-06-30 $14
2015-03-31 $-22
2014-12-31 $30
2014-09-30 $22
2014-06-30 $5
2014-03-31 $-20
2013-12-31 $15
2013-09-30 $13
2013-06-30 $10
2013-03-31 $-8
2012-12-31 $16
2012-09-30 $7
2012-06-30 $8
2012-03-31 $-7
2011-12-31 $29
2011-09-30 $2
2011-06-30 $14
2011-03-31 $-21
2010-12-31 $26
2010-09-30 $13
2010-06-30 $10
2010-03-31 $3
2009-12-31 $4
2009-09-30 $1
2009-06-30 $15
2009-03-31 $11
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.697B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00